Ausbil Investment Management Ltd Acquires 98,743 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Ausbil Investment Management Ltd lifted its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 1,215.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 106,869 shares of the biotechnology company's stock after acquiring an additional 98,743 shares during the quarter. ADMA Biologics accounts for about 1.4% of Ausbil Investment Management Ltd's holdings, making the stock its 28th largest position. Ausbil Investment Management Ltd's holdings in ADMA Biologics were worth $2,120,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. B Group Inc. bought a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $39,231,000. Raymond James Financial Inc. purchased a new stake in ADMA Biologics in the fourth quarter worth $19,076,000. Arrowstreet Capital Limited Partnership raised its stake in shares of ADMA Biologics by 57.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock valued at $47,380,000 after buying an additional 1,013,456 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock valued at $80,065,000 after buying an additional 643,661 shares during the last quarter. Finally, Man Group plc lifted its position in shares of ADMA Biologics by 305.5% during the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company's stock valued at $12,782,000 after buying an additional 561,507 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Down 2.2%

ADMA Biologics stock opened at $17.74 on Monday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. ADMA Biologics Inc has a fifty-two week low of $10.21 and a fifty-two week high of $25.67. The stock has a market cap of $4.24 billion, a P/E ratio of 20.87 and a beta of 0.47. The firm's fifty day moving average price is $20.91 and its 200-day moving average price is $18.79.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The business's revenue was up 40.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.08 EPS. Equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ADMA has been the topic of a number of research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Finally, Raymond James Financial lifted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms sold 137,931 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $20.82, for a total transaction of $2,871,723.42. Following the transaction, the director now directly owns 282,079 shares of the company's stock, valued at approximately $5,872,884.78. This trade represents a 32.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the transaction, the director now owns 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 464,621 shares of company stock worth $9,644,269. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.